a public good project by the
Synthesis
Company
of California

© 2026

David S. Rubenstein | doi.page

0 works0 citations0 h-index

David S. Rubenstein

University of North Carolina at Chapel Hill(US)North Carolina Institute of Medicine(US)Institute of Organic Chemistry(HU)Roivant Sciences (United States)(US)PerkinElmer (United States)(US)

Publications by Year

Research Areas

Dermatology and Skin Diseases, Autoimmune Bullous Skin Diseases, Food Allergy and Anaphylaxis Research, Coagulation, Bradykinin, Polyphosphates, and Angioedema, Psoriasis: Treatment and Pathogenesis

Most-Cited Works

→ Desmosome Signaling(2005)237 cited
→ Reliability and Convergent Validity of Two Outcome Instruments for Pemphigus(2009)234 cited
→ p38MAPK inhibition prevents disease in pemphigus vulgaris mice(2006)222 cited
→ Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis(2021)170 cited
→ Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent(2020)165 cited
→ Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis(2020)133 cited

→ p38MAPK Signaling and Desmoglein-3 Internalization Are Linked Events in Pemphigus Acantholysis(2010)

104 cited

→ Autoantibodies in the Autoimmune Disease Pemphigus Foliaceus Induce Blistering via p38 Mitogen-Activated Protein Kinase-Dependent Signaling in the Skin(2008)94 cited

→ In vivo blockade of pemphigus vulgaris acantholysis by inhibition of intracellular signal transduction cascades(2004)86 cited

→ One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial(2022)85 cited